These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Understanding relaxin signalling at the cellular level. Valkovic AL; Bathgate RA; Samuel CS; Kocan M Mol Cell Endocrinol; 2019 May; 487():24-33. PubMed ID: 30592984 [TBL] [Abstract][Full Text] [Related]
8. Development of a long-acting relaxin analogue, LY3540378, for treatment of chronic heart failure. Verdino P; Lee SL; Cooper FN; Cottle SR; Grealish PF; Hu CC; Meyer CM; Lin J; Copeland V; Porter G; Schroeder RL; Thompson TD; Porras LL; Dey A; Zhang HY; Beebe EC; Matkovich SJ; Coskun T; Balciunas AM; Ferrante A; Siegel R; Malherbe L; Bivi N; Paavola CD; Hansen RJ; Abernathy MM; Nwosu SO; Carr MC; Heuer JG; Wang X Br J Pharmacol; 2023 Aug; 180(15):1965-1980. PubMed ID: 36780899 [TBL] [Abstract][Full Text] [Related]
9. The anti-fibrotic actions of relaxin are mediated through AT Wang C; Pinar AA; Widdop RE; Hossain MA; Bathgate RAD; Denton KM; Kemp-Harper BK; Samuel CS FASEB J; 2020 Jun; 34(6):8217-8233. PubMed ID: 32297670 [TBL] [Abstract][Full Text] [Related]
10. Novel drug development opportunity for relaxin in acute myocardial infarction: evidences from a swine model. Perna AM; Masini E; Nistri S; Briganti V; Chiappini L; Stefano P; Bigazzi M; Pieroni C; Bani Sacchi T; Bani D FASEB J; 2005 Sep; 19(11):1525-7. PubMed ID: 16009702 [TBL] [Abstract][Full Text] [Related]
11. Serelaxin alleviates cardiac fibrosis through inhibiting endothelial-to-mesenchymal transition via RXFP1. Wilhelmi T; Xu X; Tan X; Hulshoff MS; Maamari S; Sossalla S; Zeisberg M; Zeisberg EM Theranostics; 2020; 10(9):3905-3924. PubMed ID: 32226528 [No Abstract] [Full Text] [Related]
12. The actions of relaxin on the human cardiovascular system. Sarwar M; Du XJ; Dschietzig TB; Summers RJ Br J Pharmacol; 2017 May; 174(10):933-949. PubMed ID: 27239943 [TBL] [Abstract][Full Text] [Related]
13. Relaxin and the Cardiovascular System: from Basic Science to Clinical Practice. Martins RC; Pintalhão M; Leite-Moreira A; Castro-Chaves P Curr Mol Med; 2020; 20(3):167-184. PubMed ID: 31642776 [TBL] [Abstract][Full Text] [Related]
14. The relaxin receptor as a therapeutic target - perspectives from evolution and drug targeting. Bathgate RAD; Kocan M; Scott DJ; Hossain MA; Good SV; Yegorov S; Bogerd J; Gooley PR Pharmacol Ther; 2018 Jul; 187():114-132. PubMed ID: 29458108 [TBL] [Abstract][Full Text] [Related]
15. Chronic treatment with serelaxin mitigates adverse remodeling in a murine model of ischemic heart failure and modulates bioactive sphingolipid signaling. Devarakonda T; Valle Raleigh J; Mauro AG; Lambert JM; Cowart LA; Salloum FN Sci Rep; 2022 May; 12(1):8897. PubMed ID: 35614179 [TBL] [Abstract][Full Text] [Related]
16. Relaxin family peptide receptors--from orphans to therapeutic targets. van der Westhuizen ET; Halls ML; Samuel CS; Bathgate RA; Unemori EN; Sutton SW; Summers RJ Drug Discov Today; 2008 Aug; 13(15-16):640-51. PubMed ID: 18675759 [TBL] [Abstract][Full Text] [Related]
17. Reperfusion therapy with recombinant human relaxin-2 (Serelaxin) attenuates myocardial infarct size and NLRP3 inflammasome following ischemia/reperfusion injury via eNOS-dependent mechanism. Valle Raleigh J; Mauro AG; Devarakonda T; Marchetti C; He J; Kim E; Filippone S; Das A; Toldo S; Abbate A; Salloum FN Cardiovasc Res; 2017 May; 113(6):609-619. PubMed ID: 28073832 [TBL] [Abstract][Full Text] [Related]
18. Structural Insights into the Activation of Human Relaxin Family Peptide Receptor 1 by Small-Molecule Agonists. Hu X; Myhr C; Huang Z; Xiao J; Barnaeva E; Ho BA; Agoulnik IU; Ferrer M; Marugan JJ; Southall N; Agoulnik AI Biochemistry; 2016 Mar; 55(12):1772-83. PubMed ID: 26866459 [TBL] [Abstract][Full Text] [Related]
19. Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases. Aragón-Herrera A; Feijóo-Bandín S; Anido-Varela L; Moraña-Fernández S; Roselló-Lletí E; Portolés M; Tarazón E; Gualillo O; González-Juanatey JR; Lago F J Pers Med; 2022 Jun; 12(7):. PubMed ID: 35887517 [TBL] [Abstract][Full Text] [Related]
20. The different ligand-binding modes of relaxin family peptide receptors RXFP1 and RXFP2. Scott DJ; Rosengren KJ; Bathgate RA Mol Endocrinol; 2012 Nov; 26(11):1896-906. PubMed ID: 22973049 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]